Eli Lilly and Company

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company discusses significant ongoing investments in SG&A and R&D to support growth and pipeline development but does not reference raising capital via equity or debt. - Operating margin guidance and financial outlook imply reliance on internal resources and existing financing. - Non-GAAP income and expense projections and tax rate guidance are provided, but no reference to capital raising. - No statements about issuing new shares, taking on debt, or planned fundraising activities are found in the call excerpts.

- Lilly is continuing to scale R&D and step up investments across manufacturing and commercial to support successful product launches (Page 3). - Massive investments have been made in parenteral filling capacity and API capacity, with delivery schedules taking 2 to 4 years for full impact (Page 4). - Supply capacity efforts are progressing with announced capacities from previous years ramping up, and strong growth expected in 2025 (Page 5). - There is emphasis on ramping up SG&A and R&D investments to drive demand generation activities, particularly for assets moving into phase 2 and phase 3 clinical trials (Page 6). - Investment focus includes expanding access, new clinical program starts, and broadening international market penetration, especially for type 2 diabetes and chronic pain products (Pages 4-5).

- Lilly expects strong growth driven by newly launched products Mounjaro and Zepbound, with U.S. sequential quarter-over-quarter prescriptions growing over 25%. - The company anticipates 50% revenue growth in Q4 2024 compared to the prior year, reflecting accelerating demand and supply improvements. - Demand generation efforts, including increased DTC (direct-to-consumer) advertising starting mid-November 2024, aim to further boost prescriptions. - Growth outside the U.S. is expected as new countries launch Mounjaro and Zepbound, contributing to revenue. - Lilly projects sustained operating margin expansion fueled by investments in SG&A and R&D to support commercial growth. - Supply capacity is being expanded with new manufacturing investments, allowing continued acceleration in product availability into 2025 and beyond. - The company foresees a strong 2025 with ongoing acceleration in prescriptions and sales from its leading brands across all markets.

- Eli Lilly expects continued strong revenue growth driven by new products like Mounjaro, Zepbound, and others, with increased demand and expanding access. - Operating margin expansion is expected in the short term, supported by ramped-up investments in SG&A and R&D to drive growth. - Long-term, Lilly aims to sustain and expand operating margins by justifying investments in demand generation and pipeline development. - EPS saw a significant increase to $1.19 in Q3 2024 from $0.10 in the prior year, including acquired IPR&D charges. - The company projects about 50% revenue growth for Q4 2024 with consistent demand acceleration expected into 2025. - Investments continue in manufacturing capacity and pipeline assets, indicating a focus on scalable, sustainable profit growth. - Management emphasizes balancing investment for growth with maintaining healthy operating leverage over time.

The transcript provided does not explicitly mention specific figures or detailed data regarding the current or expected orderbook or pending orders for Eli Lilly. However, key insights related to demand, supply, and market expectations include: - Strong demand growth for products Mounjaro and Zepbound, with more than 25% growth in prescriptions and underlying market growth. - Supply constraints faced in the first half of the year have eased, with supply-related customer service issues dropping from over 20% to less than 1%. - Improved manufacturing capacity and supply ramp-up expected in the next year (2025), supporting strong growth. - Demand generation efforts, including direct-to-consumer advertising (DTC), are being accelerated given improved capacity. - No demand problem identified; supply is being carefully managed to align with increasing demand. - International launches ongoing with new countries to be added, expanding product reach. No explicit orderbook or pending orders data is provided in the transcript.